BioSight
Companies
ADC Therapeutics SA logo

ADCT

NYSEEPALINGES, V8
ADC Therapeutics SA

ADC Therapeutics develops antibody-drug conjugate (ADC) therapies, a modality that combines antibodies with cytotoxic drugs to target cancer cells. The pipeline includes ZYNLONTA, an approved product, along with other candidates in preclinical and clinical development stages. ADC Therapeutics operates in the oncology space, focusing on hematologic malignancies and solid tumors.

Price history not yet available for ADCT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar